Teva Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has three hundred and twenty approved drugs.
There are thirty-two US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.
There are four hundred and thirty-six patent family members on TEVA PHARM drugs in thirty-six countries and nine hundred and sixteen supplementary protection certificates in eighteen countries.
Summary for Teva Pharm
International Patents: | 436 |
US Patents: | 32 |
Tradenames: | 268 |
Ingredients: | 260 |
NDAs: | 320 |
Patent Litigation for Teva Pharm: | See patent lawsuits for Teva Pharm |
PTAB Cases with Teva Pharm as petitioner: | See PTAB cases with Teva Pharm as petitioner |
Drugs and US Patents for Teva Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | LURASIDONE HYDROCHLORIDE | lurasidone hydrochloride | TABLET;ORAL | 208060-004 | May 17, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Teva Pharms Usa Inc | CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 212898-002 | Jun 17, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Pharms Usa | TOLTERODINE TARTRATE | tolterodine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 079141-002 | Nov 22, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva Pharms Usa | URSODIOL | ursodiol | TABLET;ORAL | 079184-002 | May 13, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-006 | Feb 20, 2020 | 8,006,690 | ⤷ Try a Trial |
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | 6,748,947 | ⤷ Try a Trial |
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 8,367,605 | ⤷ Try a Trial |
Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | 6,748,947 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
Premature patent expirations for TEVA PHARM
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Teva Pharm Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2839279 | ⤷ Try a Trial |
Taiwan | 201542252 | ⤷ Try a Trial |
Japan | 2009102408 | ⤷ Try a Trial |
Mexico | 365477 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharm Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2785706 | 2020C/516 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318 |
1632232 | SPC/GB17/007 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE HYDROCHLORIDE AND TENOFOVIR ALAFENAMIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTERED: UK EU/1/16/1112 (NI) 20160623; UK PLGB 11972/0019 20160623 |
1644019 | 2013/038 | Ireland | ⤷ Try a Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY A MESYLATE SALT; NAT REGISTRATION NO/DATE: PA0689/006/001 PA0689/006/002 |
2443246 | 2021C/538 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VAZKEPA - ICOSAPENT ETHYL; AUTHORISATION NUMBER AND DATE: EU/1/20/1524 20210329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.